Technical Analysis for ATXI - Avenue Therapeutics, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
 |
6.59 | 1.54% | 0.10 |
ATXI closed up 1.54 percent on Friday, January 18, 2019, on 1.38 times normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.
| ADX | Long-Term | Intermediate-Term | Short-Term |
|---|---|---|---|
| Strong | Up | Up | Up |
| See historical ATXI trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Jan 18 | New 52 Week Closing High | Bullish | 0.00% |
| Jan 18 | Pocket Pivot | Bullish Swing Setup | 0.00% |
| Jan 18 | Upper Bollinger Band Walk | Strength | 0.00% |
| Jan 18 | Wide Bands | Range Expansion | 0.00% |
| Jan 18 | Above Upper BB | Strength | 0.00% |
| Jan 18 | Overbought Stochastic | Strength | 0.00% |
| Jan 18 | Up 3 Days in a Row | Strength | 0.00% |
| Jan 18 | Up 4 Days in a Row | Strength | 0.00% |
| Jan 18 | Up 5 Days in a Row | Strength | 0.00% |
| Jan 18 | Upper Bollinger Band Touch | Strength | 0.00% |
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 2018-11-15
- Sector: Healthcare
- Industry: Biopharmaceuticals
Avenue Therapeutics, Inc. is a pharmaceutical company. The Company is engaged in acquiring, licensing, developing and commercializing products principally for use in the acute or intensive care hospital setting. Its product candidate is intravenous (IV) Tramadol, an intravenous formulation of tramadol hydrochloride (HCl), for the management of moderate to moderately severe postoperative pain. Tramadol, a synthetic dual-acting opioid, is a centrally acting analgesic with weak opioid agonist properties. It also works via the inhibition of serotonin and noradrenaline re-uptake and blocking nociceptive impulses at the spinal level. Tramadol is also combined with acetaminophen (APAP) or nonsteroidal anti-inflammatory drugs (NSAIDS) in clinical practice. During the year ending December 31, 2016, the Company had completed a pharmacokinetics (PK) study for IV Tramadol in healthy volunteers.
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength | |||
| Summary: | Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies. | ||
See more ATXI news...
Indicators
| Indicator | Value |
|---|---|
| 52 Week High | 6.62 |
| 52 Week Low | 2.08 |
| Average Volume | 88,393 |
| 200-Day Moving Average | 4.1088 |
| 50-Day Moving Average | 5.1865 |
| 20-Day Moving Average | 5.51 |
| 10-Day Moving Average | 5.783 |
| Average True Range | 0.4377 |
| ADX | 28.92 |
| +DI | 28.1256 |
| -DI | 8.8725 |
| Chandelier Exit (Long, 3 ATRs ) | 5.3069 |
| Chandelier Exit (Short, 3 ATRs ) | 5.8131 |
| Upper Bollinger Band | 6.4515 |
| Lower Bollinger Band | 4.5685 |
| Percent B (%b) | 1.07 |
| BandWidth | 34.174229 |
| MACD Line | 0.346 |
| MACD Signal Line | 0.2306 |
| MACD Histogram | 0.1155 |
| Fundamentals | Value |
|---|---|
| Market Cap | 66.17 Million |
| Num Shares | 10 Million |
| EPS | -0.44 |
| Price-to-Earnings (P/E) Ratio | -14.98 |
| Price-to-Sales | 0.00 |
| Price-to-Book | 1.57 |
| PEG Ratio | 0.00 |
| Dividend | 0.00 |
| Dividend Yield | 0.00% |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 7.15 | ||||
| Resistance 3 (R3) | 7.08 | 6.84 | 7.05 | ||
| Resistance 2 (R2) | 6.84 | 6.70 | 6.87 | 7.02 | |
| Resistance 1 (R1) | 6.71 | 6.61 | 6.78 | 6.78 | 6.99 |
| Pivot Point | 6.47 | 6.47 | 6.50 | 6.50 | 6.47 |
| Support 1 (S1) | 6.34 | 6.33 | 6.41 | 6.41 | 6.19 |
| Support 2 (S2) | 6.10 | 6.24 | 6.13 | 6.16 | |
| Support 3 (S3) | 5.97 | 6.10 | 6.13 | ||
| Support 4 (S4) | 6.04 |
